12 Best Boutique M&A Advisors in Boston for $5M-$200M Deals (2026)

Last updated: May 2026

We run Peony, a data room platform for M&A and private equity. Boston is one of the seven US metros (San Francisco, Dallas, Chicago, Atlanta, Houston, NYC, and LA being the others) where we see the most boutique M&A advisor deal flow on the platform. The reason is structural: Boston is the national capital of biotech and life-sciences M&A (Cambridge / Kendall Square biotech corridor, the Longwood medical area, Mass General Brigham Ventures), the densest US healthcare-services M&A market (physician practices, home health, specialty pharmacy, behavioral health), a steady-state SaaS and tech M&A ecosystem (Boston metro SaaS funding rose 22.3% YoY to $1.03B in 2025 across 46 rounds with 18 acquisitions versus 16 the prior year, per Tracxn), and the Massachusetts metro where the IPO-vs-M&A pivot is sharpest in 2026 -- 1 MA-based biotech IPO in all of 2025 versus 6 in 2024, per the MassBio Year-End Funding Report.

I co-founded Peony after eight years on the investor side -- first as a venture capitalist at Backed VC, then as a growth equity investor at Target Global covering late-stage and secondary deals -- and a brief earlier stint in M&A at Nomura. Across those roles I evaluated hundreds of deals from the buyer's chair, sat through dozens of management presentations from sell-side advisors, and watched the same handful of mistakes ruin good deals: bad CIMs, disorganized data rooms, advisors who could not answer customer concentration questions in real time, and seller-side processes that lost momentum because nobody could tell which buyer was actually engaged. Now at Peony I work directly with dozens of M&A advisors, independent sponsors, and PE deal teams running diligence across our platform. Building this Boston guide as part of our city series -- see also our SF/Bay guide, NYC guide, LA guide, Dallas guide, Chicago guide, Atlanta guide, and Houston guide.

This guide maps 12 verified Boston-headquartered or Boston-led boutique M&A advisory firms active in the $5M-$200M EV deal range as of May 2026. Every firm has been verified for Boston-area presence, deal size band, and recent transaction activity. Bulge-bracket banks (Goldman Sachs Boston, Morgan Stanley Boston, JPMorgan Boston) and elite-boutique upper-tier specialists are excluded by design -- their structural sweet spot is $200M+ deals, and a $25M-$200M sell-side at any of those firms is a B-team engagement. Generalist boutiques whose primary book is below $5M EV (true business-broker shops) are also excluded.

TL;DR: Boston sits at the intersection of biotech and life-sciences M&A (Aquilo Partners' Durect ALZET sale to Lafayette Instrument November 2024 for $17.5M, Outcome Capital's RealizedCare sale to XRHealth February 2025), healthcare-services rollups (Provident Healthcare Partners' Acentus sale to Henry Schein January 2025), generalist middle-market business services (Mirus Capital's Sassafras Software sale to TeamDynamix April 2025, BellMark Partners' Vital Delivery Solutions sale to Copley Equity Partners December 2025), full-service middle-market platform reach (Capstone Partners' acquisition of TM Capital December 2025), tech specialty (AGC Partners' Mobalytics sale to ESL FACEIT March 2025), and adtech / digital-media (Progress Partners' Content Lab sale to SAMY Alliance January 2025). Massachusetts biopharma in 2025 logged 36 MA-based companies acquired for a total of $20B per MassBio, anchored by Sanofi's June 2025 agreement to acquire Cambridge's Blueprint Medicines for $9-9.5B (the largest Boston-area biotech M&A of 2025) per BioPharma Dive, and Eli Lilly's June 2025 acquisition of Verve Therapeutics plus October 2025 acquisition of Adverum Biotechnologies. For Boston founders selling between $5M and $200M, the right answer is almost always a Boston specialty boutique: Provident Healthcare Partners, Outcome Capital, Aquilo Partners' Boston office, and Back Bay Life Science Advisors in the Healthcare and Life-Sciences band; Mirus Capital Advisors, BellMark Partners, and Capstone Partners in the Generalist Middle-Market band; AGC Partners, Covington Associates, Progress Partners, and Shields & Company in the Tech / Adtech / Multi-Sector Specialty band; and Cain Brothers as the bank-owned-boutique-tier healthcare anchor. Below: the firms, the deal-size bands, the fees, and five recent verified Boston-tied closes that show how the metro's market actually works.

---

How Did I Verify This List?

Every firm on this list passes four filters:

1. Boston-area headquarters or principal Boston office -- Boston, Cambridge, Wellesley, Burlington, Needham, Waltham, or the broader Route 128 / I-495 corridor; not a satellite branch staffed by a single analyst
2. Verifiable transaction record -- closed at least 5 transactions in the $5M-$200M EV range in the last 36 months, sourced from press releases, BusinessWire and PR Newswire announcements, SEC EDGAR filings, or firm transaction walls
3. Active 2024-2026 deal activity -- not a legacy firm coasting on pre-2020 relationships
4. Lower-middle-market core -- modal deal size in the $5M-$200M EV band; firms whose primary book is below $5M EV (true Main-Street brokers) or above $300M EV (where geography stops mattering and bulge-bracket banks dominate) are excluded

I cross-referenced firm websites against Axial's 2024-2025 Top 100 LMM Investment Bank rankings, the MassBio Year-End Funding Report, the Foley Hoag Healthcare and Life Sciences Deal Trends 2025 review, the ACG Boston chapter, and individual firm press releases for verified 2024-2026 transaction history. Where a firm claimed Boston leadership but the senior team was actually based elsewhere, I dropped it. Bulge-bracket Boston offices (Goldman Sachs Boston, Morgan Stanley Boston, JPMorgan Boston, Citi Boston, BofA Boston) and elite-boutique upper-MM specialists are excluded by design -- their structural sweet spot is $200M+ deals and the $25-200M EV Boston seller is a B-team client at those firms.

Three caveats on the Boston specialty bench:

First, Cain Brothers is included with explicit framing as a bank-owned-boutique-tier firm rather than a true independent. The firm is a division of KeyBanc Capital Markets (acquired by KeyCorp in 2018) and the Boston-area healthcare practice operates within the KeyBanc franchise rather than as a standalone boutique. The structural caveat is the same one we applied to Houlihan Lokey in the LA and NYC guides -- the firm earns a place because the senior team and franchise depth are real, but the parent-bank ownership shapes the deal-team experience.

Second, Capstone Partners is Boston-headquartered but Huntington Bancshares-owned (acquired June 16, 2022) and operates as a bank-owned platform tier rather than a true independent boutique. Capstone's December 2025 acquisition of TM Capital folded the legacy TM Boston team into the Capstone roster -- worth a paragraph below in the firm profile.

Third, TM Capital's standalone Boston team has been folded into Capstone Partners as of December 2025, so we do not list TM Capital separately. Bigelow LLC (Massachusetts roots, 1935 founding) is excluded because the firm's modal deal size is below the $30-50M EV mid-market band we cover. NewDelta Capital Partners (Boston, founded 2009) is excluded because its consumer-only platform is too narrow for a generalist guide.

Deqian Jia, my co-founder, adds the technical readiness lens here:

"Across the Boston-area data rooms we host, the gap between advisors who consistently close in 6 months and those who run 12-month processes is preparation. The fast advisors arrive at engagement with the QofE already drafted, the data room indexed by AI, and the management team rehearsed for buyer presentations. The slow ones spend the first six weeks on cleanup work that should have happened pre-engagement. Boston's structural confidentiality risk is unusually high for biotech specifically -- the Cambridge biotech ecosystem is under 2 square miles, the same handful of venture firms cover the majority of Series A-through-C biotech investments, and senior scientific talent moves between competing programs on 18-30 month cycles. When you're picking a Boston advisor, ask to see a sample data room from a recent close -- not a pitch deck. The folder structure tells you everything." -- Deqian Jia, Peony co-founder

---

Quick Comparison Table

---

Why Is Boston the M&A Capital for Biotech, Healthcare, and Life-Sciences Deals?

Boston's M&A market is structurally distinct from every other US metro in five ways, and each one shows up in the deal-size bands and advisor specialty mix. First, the biotech M&A volume is national-leading: Massachusetts biopharma in 2025 logged 36 MA-based companies acquired for total deal value of $20B per the MassBio Year-End Funding Report, anchored by Sanofi's June 2025 agreement to acquire Cambridge-based Blueprint Medicines for $9-9.5B per BioPharma Dive (the largest Boston-area biotech M&A of 2025), Eli Lilly's June 2025 acquisition of Verve Therapeutics, Eli Lilly's October 2025 acquisition of Adverum Biotechnologies, and Pfizer's $10B Metsera acquisition per Foley Hoag's December 2025 deal-trends review. The MA biopharma pipeline grew 14% YoY in 2025 versus 6.8% nationally, and MA-based or MA-presence companies received 28 FDA approvals in 2025 per MassBio.

Second, the IPO market is essentially closed for MA biotech: 1 MA-based biotech IPO in all of 2025 (Sionna Therapeutics, Waltham, IPO'd February 2025 raising approximately $219.2M) versus 6 MA biotech IPOs in 2024 per MassBio. The default exit narrative has flipped to M&A-first for clinical-stage Boston biotech founders, and the IPO-vs-M&A pivot is the Boston-distinguishing exit-decision question of 2026.

Third, the lab real-estate cost structure is under unprecedented pressure: Boston life-science vacancy hit an all-time high of 28% by Q4 2025 with 17M sq ft available per CBRE's Q4 2025 report, structurally pressuring sub-clinical-stage biotechs into strategic-exit conversations rather than another lease-renewal cycle. The vacancy rate translates directly into M&A volume because biotechs cannot indefinitely sustain Cambridge lab burn rates without either a clinical inflection-point or a strategic-acquirer outcome.

Fourth, the healthcare-services M&A density is structural: Boston's hospital-system concentration (Mass General Brigham, Beth Israel Lahey Health, Boston Children's, Tufts Medicine, Boston Medical Center, Lahey Hospital and Medical Center) anchors a healthcare-services rollup ecosystem that runs through Boston-area boutiques continuously. Provident Healthcare Partners alone logged 4 verified 2025 closes across CGM medical supply, home health, specialty infusion, and healthcare-procurement software.

Fifth, the SaaS and tech M&A market is steady-state but selective: Boston metro SaaS funding rose 22.3% YoY to $1.03B in 2025 across 46 rounds per Tracxn, with 18 SaaS acquisitions in Boston in 2025 versus 16 in 2024 -- not the AI-fueled volume surge of SF/Bay but a healthy steady-state with consistent strategic-buyer interest.

The structural takeaway: Boston is the densest M&A market in the country for biotech, biopharma, healthcare-services, and life-sciences-tools at the LMM band, and the right advisor is almost always a sub-vertical specialty boutique built around the $5M-$200M EV band -- with two bank-owned platform exceptions (Cain Brothers, Capstone Partners) and one cross-coast biotech anchor (Aquilo Partners' Boston office).

---

What Should I Look For in a Boston M&A Advisor?

Five filters that matter more in Boston than in other US metros:

1. Sub-vertical specialty depth -- "healthcare generalist" is not enough in Boston where biotech, biopharma, medical devices, diagnostics, healthcare services, digital health, and HCIT are all distinct sub-sectors with different buyer pools and different diligence cycles. The right advisor names five recent buyers in your specific sub-vertical without having to look them up.
2. Senior-banker engagement -- the Boston LMM band ($25M-$200M EV) requires senior bankers personally on every buyer call. Boutiques like Provident Healthcare, Outcome Capital, Aquilo Partners' Boston office, BellMark Partners, AGC Partners, and Mirus Capital run senior-banker models structurally; bank-owned-tier firms (Cain Brothers, Capstone) sometimes delegate to VPs and analysts because the parent-bank cost structure spreads MD time across multiple mandates.
3. Cambridge confidentiality discipline -- the Kendall Square biotech ecosystem is unusually leak-prone, and the right advisor walks through their confidentiality protocol structurally before pitching the engagement. Vista Point's founder-only model is the SF analog; the Boston analogs are Aquilo's regulatory-NDA-default biotech model, Outcome Capital's strategy-led-senior-only model, and Back Bay Life Science Advisors' integrated banking-and-consulting model.
4. Massachusetts hospital-system relationships -- if your buyer set includes any of the regional hospital systems (Mass General Brigham, Beth Israel Lahey, Tufts Medicine), ask the advisor to walk through their last three closes involving any of those systems. Provident Healthcare and Cain Brothers have the deepest hospital-system buyer-relationship density in Boston.
5. Sub-IND biotech mandate willingness -- if your transaction is a sub-IND or pre-clinical biotech with an asset valuation in the $20-100M EV range, ask whether the firm has a $750K minimum success fee floor. Most bulge-brackets do; most Boston specialty boutiques don't. The minimum-fee question separates structurally-aligned advisors from misaligned ones.

For pricing comparisons across data room platforms, our pricing guide covers what the Boston specialty boutiques typically charge and how that compares to bulge-bracket alternatives. For confidentiality and watermarking specifically, Peony embeds buyer email plus exact view timestamp into every page of every CIM.

---

Which Boston M&A Advisors Anchor the Healthcare and Life-Sciences Band ($10M-$500M EV)?

For Boston-area healthcare and life-sciences founders, four firms anchor the LMM band: Provident Healthcare Partners (Boston; healthcare-services rollups; founded 1998), Outcome Capital (Boston; medical devices, diagnostics, life-sciences services), Back Bay Life Science Advisors (Boston; biopharma, medtech, integrated banking-and-strategy-consulting; founded 2010), and Aquilo Partners' Boston office (San Francisco firm; deep biopharma specialty; John Dyer leads in Boston). The first call splits structurally on sub-vertical: healthcare-services rollups to Provident, medical devices and diagnostics with strategy-consulting scope to Outcome Capital, sub-IND biopharma to Back Bay LSA, and biopharma at $50M+ EV to Aquilo.

1. Cain Brothers (a division of KeyBanc Capital Markets)

HQ: New York (Cain Brothers main); Cleveland (KeyBanc Capital Markets parent); Boston-area senior bankers cover New England HCIT, home health, behavioral health, and specialty pharmacy Founded: 1982 (NYC original founding); acquired by KeyCorp in 2018; now operates as "Cain Brothers, a division of KeyBanc Capital Markets" Senior team: Cain Brothers brings 100+ healthcare bankers across the country with continuous Boston-area presence. Recent senior hires include Patrick Allen (Managing Director, healthcare investment banking; joined July 2024 from Piper Sandler & Company), Thad Davis (Managing Director, Healthcare Technology and Services; Head of Healthcare Private Placements; joined 2024 from Leerink), David Cohen (Managing Director), and Matt Margulies (Managing Director focused on home health, hospice, specialty pharmacy, and durable medical equipment). Deal size sweet spot: $50M-$1B+ healthcare M&A (covers full cap structure with KeyBanc parent) Sectors: Healthcare services, healthcare IT, home health and hospice, specialty pharmacy, medical-supply distribution, durable medical equipment, behavioral health, payer tech, life-sciences services Recent activity: Cain Brothers has remained continuously active in healthcare-services rollups and HCIT M&A through 2025 with senior-team additions through Q1-Q2 2025; specific Boston-led 2024-2026 deal disclosure is best verified directly via the firm's transaction wall at cainbrothers.com.

Distinguishing factor: Cain Brothers is the largest dedicated healthcare-specialty M&A team with continuous Boston-area coverage; the KeyBanc Capital Markets parent provides full debt and equity capital markets capability that an independent boutique cannot match, including syndicated lending and structured-finance capability for buyers requiring staple financing. Frame Cain Brothers as "KeyBanc Capital Markets healthcare-specialty division" rather than independent boutique -- the parent ownership structure is a relevant disclosure for sellers evaluating senior-banker autonomy and engagement-letter-term flexibility.

Best for: Digital-health, healthtech, healthcare-services, behavioral-health, and HCIT founders with $25M+ revenue who want a healthcare-specialty senior team plus a balance-sheet-capable parent. For Boston-area founders specifically, Cain Brothers is the bank-owned-boutique-tier alternative to true independents like Provident Healthcare or Outcome Capital.

2. Provident Healthcare Partners

HQ: 260 Franklin Street, Suite 1900, Boston, MA 02110 (LA office secondary) Founded: 1998 -- Boston-headquartered Senior team: Kevin Palamara (Managing Director; with the firm since 2002; led Acentus to Henry Schein in January 2025), Rebecca Leiba (Senior Managing Director, Boston), Eric Major (Managing Director, Boston; joined 2012), Michael Patton (Managing Director), Steven Aguiar (Managing Director, LA office), and Craig R. Sager (Managing Director). The firm is privately held; specific founders are not publicly named in firm communications -- Boston founders evaluating Provident should evaluate the firm on the depth and continuity of the current Managing Director bench rather than founding-team pedigree. Deal size sweet spot: $20M-$300M healthcare-services M&A Sectors: Pure middle-market healthcare services -- physician practices, home health and hospice, specialty pharmacy, infusion, durable medical equipment, behavioral health, dental services Verified 2025 transactions:

• Acentus sold to Henry Schein (January 2025) -- Provident exclusive financial advisor to Acentus (continuous glucose monitoring medical supplier); Kevin Palamara led the engagement
• Elder Care Homecare sold to Rallyday Partners (August 2025) -- Provident exclusive financial advisor to Elder Care Homecare
• CPS Infusion sold to Seven Hills Capital (September 2025) -- Provident exclusive financial advisor to CPS Infusion
• Meperia sold to Diversis Capital (November 2025) -- Provident exclusive financial advisor to Meperia (healthcare-procurement software)

Distinguishing factor: Provident is the deepest-rooted Boston-headquartered healthcare-services M&A boutique with 28 years of continuous middle-market focus and a verified four-deal 2025 track record across CGM medical supply, home health, specialty infusion, and healthcare-procurement software. The firm's single-vertical depth means every banker on staff has direct visibility into which PE platforms, healthcare strategics, and PE-rollup funds are filling pipeline gaps in physician services, home health, and specialty pharmacy.

Best for: Healthcare-services founders with $5M-$30M EBITDA in physician practices, home health and hospice, specialty pharmacy, infusion, durable medical equipment, behavioral health, or dental services preparing for a strategic acquirer or PE-platform exit. Best contact: Kevin Palamara.

3. Back Bay Life Science Advisors (BBLSA)

HQ: Back Bay neighborhood, Boston, MA Founded: 2010 -- co-founded by a life-science investment banker and a life-science strategic consultant who paired investment-banking-execution capability with strategy-consulting-led pre-engagement diligence. Specific founder names are best confirmed directly via the firm's leadership page at bblsa.com -- Boston founders should evaluate BBLSA on the integrated banking-and-strategy-consulting model rather than founding-team pedigree alone. Senior team: Peter Bak, PhD (Partner and Managing Director; promoted December 2020; immuno-oncology PhD from Dartmouth, postdoctoral fellowship at MIT Koch Institute) anchors the senior bench. The full leadership team is detailed at bblsa.com. Deal size sweet spot: $10M-$500M biopharma and medtech M&A and licensing Sectors: Biopharma, medtech, diagnostics, life-sciences tools -- integrated investment-banking-and-strategy-consulting model Recent activity: BBLSA's 2023 partnership with DNB Bank (Norway's largest bank) gives the firm cross-border European acquirer reach unusual for a Boston-area life-sciences boutique. The firm tracks US-China biotech transactions including Verdiva Bio's $411M January 2025 deal, Candid's WuXi licensing transaction valued at $925M in January 2025, and Avenzo's bispecific licensing with DualityBio for $50M in January 2025 -- BBLSA's specific advisor role on each transaction is best verified directly with the firm before relying on the deal in advisor-track-record evaluation.

Distinguishing factor: BBLSA's integrated banking-and-strategy-consulting model is structurally distinct on the East Coast -- the same senior team runs strategy, valuation, buyer-pool design, and transaction execution, which produces deeper pre-engagement diligence than process-only firms. The DNB Bank partnership extends cross-border European acquirer reach.

Best for: Sub-IND biotech and biopharma founders preparing for a strategic acquirer with significant pre-engagement strategy-consulting scope -- the model fits situations where the asset valuation is highly uncertain and the buyer-pool design needs to pair scientific-strategy framing with transaction-execution capability.

4. Outcome Capital

HQ: Boston / Wellesley metro Founded: Originally as WWC Securities in 1998; rebranded to Outcome Capital in September 2012 with the launch of the Boston-based life sciences and healthcare practice (Wellesley office) Senior team: Arnie Freedman (Founder and Managing Partner), Dr. Oded Ben-Joseph (Co-Founder and Managing Partner; previously Managing Director at Boston Equity Advisors; PhD scientist), Peter F. Meyer, PhD (Managing Director, Boston; joined February 2025; expanding the medical-device and life-science-services practices), and Thomas Busby (promoted to Director; medical-device and life-science-services practice). Deal size sweet spot: $10M-$150M life-sciences and healthcare M&A Sectors: Life sciences and healthcare -- biotech, diagnostics, medical devices, life-science services, pharma Verified 2025 transactions:

• RealizedCare sold to XRHealth (February 2025) -- Outcome Capital exclusive strategic and financial advisor to RealizedCare; RealizedCare's CEO Aaron Gani became General Manager of XRHealth US post-close

Distinguishing factor: Outcome Capital runs the strategy-led-execution model on the East Coast -- the senior team brings strategy-consulting-style pre-engagement diligence (asset positioning, valuation triangulation, buyer-pool design) layered onto transaction-execution capability. Ben-Joseph's PhD-scientist background and Meyer's deep medical-device pedigree (joined February 2025) anchor the medtech and diagnostics practices. The firm's strategy-consulting-plus-investment-banking integrated approach is closest to Back Bay LSA's model on the Boston bench, with Outcome Capital deeper in medical devices and Back Bay deeper in biopharma.

Best for: Medical-device, diagnostics, life-science-services, and biotech founders with $10M-$50M EBITDA preparing for a strategic acquirer where the engagement scope includes strategy-consulting work alongside transaction execution. Best contact: Arnie Freedman or Oded Ben-Joseph (founder-tier).

5. Aquilo Partners (Boston Office)

HQ: San Francisco (firm headquarters at 601 California Street); Boston office (and NYC office) Founded: 2002-2003 -- co-founded by Jim Zanze and John Rumsey (life-sciences investment banking veterans; Zanze previously Managing Director and Head of Private Placements at JPMorgan and Hambrecht & Quist) Boston-office Managing Director: John Dyer (Managing Director; joined Aquilo in 2009 from JPMorgan biotech investment banking) leads the Boston bench. Other senior team members include David Metzger (now leads the New York office), Jason Yip, and the SF founders. Deal size sweet spot: $50M-$500M+ biotech M&A and licensing Sectors: Pure life sciences -- biopharma, biotech, medtech, tools, diagnostics, gene therapy. $30B+ in completed transactions over firm lifetime, $15B+ in M&A and partnering, $8B+ in capital raised. Verified 2024-2025 transactions:

• Durect's ALZET line sold to Lafayette Instrument Co. (November 2024) -- $17.5M; Aquilo Partners advisor to Durect (osmotic-pump research-tools product line)
• Adverum Biotechnologies sold to Eli Lilly (announced October 24, 2025; closed December 9, 2025) -- Aquilo Partners exclusive financial advisor to Adverum on the gene-therapy acquisition (Adverum's lead asset is Ixo-vec, an intravitreal gene therapy for wet age-related macular degeneration); deal value up to approximately $261.7 million inclusive of contingent value rights
• Oncology diagnostics financing (AI / morphology platform) -- $20.7M in August 2024; Aquilo Partners advisor

Distinguishing factor: Aquilo is the deepest life-sciences-only specialty boutique with cross-coast presence (SF + Boston + NYC) -- approximately 15 dedicated bankers, the senior team coming from the buy-side life-sciences specialty fund and Wall Street IB world, and direct visibility into which large-cap pharma corp-dev teams (Pfizer, Eli Lilly, Bristol-Myers Squibb, Merck, Sanofi, Novartis, AstraZeneca, Johnson & Johnson) are filling pipeline gaps. The cross-coast model means a Boston biotech founder gets the same senior team as an SF biotech founder -- unusual on the boutique bench.

Best for: Boston-area biopharma, biotech, medtech, and diagnostics founders preparing for a strategic acquirer or out-licensing transaction at the $50M-$500M EV band. Best contact: John Dyer (Boston Managing Director).

---

Which Boston M&A Advisors Anchor the Generalist Middle-Market Band ($10M-$500M EV)?

For Boston-area generalist sellers in business services, consumer products, industrial, food and beverage, and multi-sector situations, three firms anchor the LMM band: Mirus Capital Advisors (Burlington MA; founded 1987 -- the deepest-rooted New England generalist boutique), BellMark Partners (Boston + Cleveland; founded 2009 by Dave Gesmondi with KeyBanc and Covington pedigree), and Capstone Partners (Boston-headquartered; Huntington Bancshares subsidiary; full-service middle-market platform with 12 industry groups). The first call breaks on size and ownership structure: smaller founder-led generalist deals to Mirus, mid-sized senior-banker-driven business-services deals to BellMark, and larger deals where bank-owned-platform reach matters to Capstone.

6. Mirus Capital Advisors

HQ: 200 Summit Drive, Floor 4, Burlington, MA 01803 (phone 781-418-5900) Founded: 1987 -- 38+ years of continuous New England M&A practice with 300+ closed transactions; the deepest-rooted New England-based generalist boutique Senior team: Andrew Crain (President; 20+ years experience; food-and-beverage, consumer, industrial, healthcare focus), Mark Young (Partner; M&A advisory across founder-owned and PE-backed growth situations; led the INNO4 to ServicePoint deal awarded "USA Growth Equity Deal of the Year"), Jason Arican (Director; software and SaaS lead; led Sassafras Software to TeamDynamix sale). Deal size sweet spot: $10M-$100M generalist middle-market M&A Sectors: Generalist middle-market -- consumer products, industrial, business services, healthcare, technology and SaaS, food and beverage, manufacturing and distribution Verified 2024-2025 transactions:

• Sassafras Software sold to TeamDynamix (April 23, 2025) -- Mirus Capital exclusive financial advisor to Sassafras Software; Jason Arican led the engagement
• Mikros Technologies sold to Jabil (October 1, 2024) -- Mirus Capital exclusive financial advisor to Mikros
• INNO4 sold to ServicePoint -- Mirus Capital advisor; Mark Young led; the deal was awarded "USA Growth Equity Deal of the Year"

Domain note: Mirus operates from the merger.com domain, not miruscapital.com -- senders contacting the firm should use the merger.com address pattern (e.g., arican@merger.com, young@merger.com, crain@merger.com).

Distinguishing factor: Mirus is the longest-operating Boston-area generalist M&A boutique with 38+ years and 300+ closed transactions, and the firm's sector breadth (consumer, industrial, services, healthcare, tech, F&B) makes it the structural default for Boston-area founder-owned businesses with multi-sector or hard-to-categorize asset profiles.

Best for: Founder-owned New England businesses with $10M-$50M EBITDA in consumer products, industrial, business services, food and beverage, or SaaS preparing for a strategic acquirer or PE-platform exit. Best contact: Jason Arican for tech and SaaS, Mark Young for general M&A advisory, Andrew Crain (President) for cross-sector situations.

7. BellMark Partners

HQ: Boston (primary office) + Cleveland office Founded: 2009 by Dave Gesmondi (formerly KeyBanc Capital Markets M&A Cleveland; founding officer of Covington Associates' Consumer and Industrial M&A practice) Senior team: Dave Gesmondi (Managing Director, Head of Boston; founder; 25+ years experience), Mike Kent (Managing Director, Boston; 25+ years across business services, healthcare, consumer, industrial), David Evatz (Managing Director, Boston; joined April 2025; 25+ years). Deal size sweet spot: $20M-$200M generalist middle-market M&A Sectors: Generalist middle-market -- business services, healthcare, consumer, industrial Verified 2025 transactions:

• Vital Delivery Solutions sold to Copley Equity Partners (December 18, 2025) -- BellMark Partners exclusive financial advisor to Vital Delivery Solutions; deal team included David Gesmondi, Kellen Field, and Christopher Rea
• Stratford Pharmaceuticals deal (2024-2025) -- BellMark Partners advisor; transaction details verified at bellmarkpartners.com transactions page

Distinguishing factor: BellMark runs a senior-banker-only model anchored by founder Dave Gesmondi's KeyBanc and Covington pedigree, with the Cleveland office adding Midwest buyer-pool reach beyond the New England core. The April 2025 hire of David Evatz expanded the senior bench.

Best for: Founder-owned and PE-backed business-services, healthcare, consumer, and industrial sellers with $5M-$25M EBITDA preparing for a senior-banker-led process. Best contact: Dave Gesmondi (founder); Mike Kent for business-services depth; David Evatz for the recent senior-bench addition.

8. Capstone Partners

HQ: 176 Federal Street, 3rd Floor, Boston, MA 02110 -- Boston-headquartered Capstone Partners is a Huntington Bancshares subsidiary (acquired June 16, 2022); Boston headquarters retained post-acquisition Founded: Capstone Partners was incorporated in 2002 by current President John Ferrara (originating in 2001 as a wholly-owned subsidiary of Arthur Andersen); merged with Denver-based Headwaters MB in 2018 (rebranded to "Capstone Headwaters," then back to "Capstone Partners" in April 2021); acquired by Huntington Bancshares June 16, 2022; acquired TM Capital December 2025 -- the December 2025 TM Capital acquisition folded the legacy TM Boston team into the Capstone roster Senior team: John Ferrara (Founder and President; now CEO of the combined Capstone-TM entity; Boston-based), Crista Gilmore (Managing Director, Building Products and Construction Services Group; promoted March 21, 2025; 15+ years M&A experience; CFA + CPA), Geoffrey Frankel (Managing Director, Special Situations Investment Banking lead). TM Capital legacy bankers folded in include Brad Adams (Managing Director, Tech and Tech-Enabled Services; Boston) and Kevin Atchue (Managing Director). Email migration from @tmcapital.com to @capstonepartners.com is in progress as of mid-2026 -- confirm the current address before sending the engagement letter. Deal size sweet spot: $25M-$500M middle-market M&A Sectors: 12 industry groups -- building products and construction services, business services, consumer, energy, financial services, food and beverage, healthcare, industrial growth, technology and media, special situations Recent activity: Capstone's December 2025 acquisition of TM Capital is the major 2025 development for the Boston bench. Crista Gilmore's March 2025 promotion to Managing Director expanded the building products and construction services group leadership. Capstone Partners also publishes the Middle Market M&A Valuations Index, a widely-cited industry data source.

Distinguishing factor: Capstone is the largest Boston-headquartered full-service middle-market M&A platform, anchored by Huntington Bancshares parent ownership and December 2025 TM Capital acquisition. The 12 industry groups give the firm cross-vertical reach unmatched among true-independent Boston boutiques. The trade-off: parent-bank compliance overhead can slow engagement-letter negotiations and shape deal-team comms protocols differently from the true independents.

Best for: Founder-owned and PE-backed sellers with $5M-$50M EBITDA in any of Capstone's 12 industry groups who want bank-owned-platform reach plus Boston-headquartered senior team. The special situations practice (Geoffrey Frankel) is particularly valuable for sellers with covenant-default risk or distressed-buyer dynamics. Best contact: John Ferrara (CEO of combined Capstone-TM entity).

---

Which Boston Boutiques Cover Tech, Adtech, and Multi-Sector Specialty ($10M-$200M EV)?

For Boston-area founders in technology, software, adtech, digital media, and multi-sector situations, four firms anchor the band: AGC Partners (Boston-headquartered; pure tech and SaaS specialty; founded 2003), Covington Associates (Boston; multi-sector with healthcare, business services, consumer, tech depth; founded 1991), Progress Partners (Wellesley MA; pure adtech and digital-media specialty; founded 2002), and Shields & Company (Greater Boston; generalist with multi-sector breadth; founded 1991). The first call splits structurally on sub-vertical: pure SaaS or AI to AGC, healthcare-services or consumer with tech crossover to Covington, adtech or digital media to Progress, and multi-sector with services or consumer or industrial to Shields.

9. AGC Partners

HQ: 99 High Street, 22nd Floor, Boston, MA 02110 (phone 617-261-4100) -- pure Boston-headquartered firm Founded: 2003 by Ben Howe (Founder and CEO; former head of M&A at S.G. Cowen), Jon Guido (Co-Founder), and Maria Lewis Kussmaul (Co-Founder and Partner; previously a long-time ranked analyst at S.G. Cowen) Senior team: Ben Howe (Founder and CEO), Jon Guido (Co-Founder), Maria Lewis Kussmaul (Co-Founder and Partner; cybersecurity sector lead; previously at S.G. Cowen), Russ Workman (Partner; cybersecurity and defense-technologies; previously Jefferies plus USAF intelligence), Nate Hennings (led the Mobalytics to ESL FACEIT Group deal in March 2025), Michael Howe (led the Protecht $280M PSG investment in March 2025). Deal size sweet spot: $50M-$1B+ tech M&A Sectors: Pure technology -- AI, SaaS, vertical software, cybersecurity, defense tech, fintech, healthtech-software, education tech Verified 2025 transactions:

• Mobalytics sold to ESL FACEIT Group (March 2025) -- AGC Partners sole financial advisor to Mobalytics; Nate Hennings led; ESL FACEIT Group is owned by Saudi PIF / Savvy Games Group
• Protecht $280M PSG Equity investment (2025) -- AGC Partners advisor to Protecht (Australian governance, risk, and compliance software); Michael Howe led
• AccountantsWorld sold to IRIS (2025) -- AGC Partners advisor; IRIS is a Hg Capital portfolio company

2025 portfolio scale: AGC closed 28 deals in 2025 with 40 new mandates added per the firm's published figures; AGC's published claim of leading tech M&A boutique activity over its operating period is widely cited but should be evaluated against independent league-table sources (Mergermarket, Refinitiv) when used in advisor selection.

Distinguishing factor: AGC runs six annual industry conferences across pure-tech sub-verticals -- the conference circuit is the firm's structural buyer-relationship engine and translates directly into wider buyer pools at engagement time. The firm's sector specialization (AI, SaaS, vertical software, cybersecurity, defense tech, fintech) is deeper than any other Boston-headquartered tech boutique.

Best for: $30M-$200M ARR SaaS, AI-infrastructure, cybersecurity, defense-tech, fintech, edtech, and healthtech-software companies running competitive sale processes where buyer-pool breadth and conference-circuit relationships matter.

10. Covington Associates

HQ: 99 Summer Street, Suite 200, Boston, MA 02110 (plus Chicago and NYC offices) Founded: 1991 by Christopher (Chris) Covington (previously co-founder and managing partner of Volpe & Covington, an SF tech and healthcare investment bank) Senior team: Chris Covington (Founder and Managing Director; long-standing relationship with Inverness Medical involving approximately 30 transactions and $6B+ aggregate value), Tom Cibotti (Managing Director; joined 1993; 20+ years business services, healthcare, and technology M&A experience), Ben Dunn (Managing Director, Boston), Chris Tashjian (Managing Director, Boston), Scott Fisher, Grant Grava, Tim McMahon, and Michael Papile (additional Managing Directors per the firm's leadership page). Deal size sweet spot: $25M-$200M middle-market M&A Sectors: Healthcare, business services, consumer and industrial, technology and software -- approximately 252 lifetime deals Verified 2025-2026 transactions:

• CounselEAR sold to Fullsteam (December 30, 2025) -- Covington Associates advisor to CounselEAR
• General advisory engagement with WestView Capital Partners (2025)
• General advisory engagement with 28bio (2026)

Domain note: Covington operates from the covllc.com domain, not covingtonassociates.com or covingtonllc.com -- senders contacting the firm should use the covllc.com address pattern (e.g., ccovington@covllc.com).

Distinguishing factor: Covington's 35-year continuous New England M&A practice and approximately 252 lifetime deals make it one of the longest-operating Boston-area multi-sector boutiques. The firm's sector breadth (healthcare, business services, consumer, industrial, tech) and the Inverness Medical decades-long relationship anchor the senior bench. Sister practice Volpe & Covington built the firm's tech and healthcare pedigree.

Best for: Multi-sector founder-owned businesses with $5M-$25M EBITDA in healthcare-services, business services, consumer, industrial, or technology preparing for a senior-banker-led process. Best contact: Chris Covington (founder-tier).

11. Progress Partners

HQ: Wellesley, MA + NYC office Founded: 2002 by Nick MacShane (sister venture-fund Progress Ventures runs a complementary VC strategy; Progress Ventures' fourth fund is approximately $35M) Senior team: Nick MacShane (Founder and Senior Managing Director; career deals include AdsWizz to Pandora, Going.com and PrecisionDemand to AOL, financings for Tremor Media, ContextWeb, MediaMath). Deal size sweet spot: $15M-$150M adtech and digital-media M&A Sectors: Pure adtech, martech, digital media, programmatic, data privacy -- approximately 40+ closed transactions over 20+ years Verified 2024-2025 transactions:

• Content Lab sold to SAMY Alliance (January 2025) -- Progress Partners advisor to Content Lab
• Pathlabs sold to MiQ (September 4, 2024) -- Progress Partners advisor
• Sabre Systems sold to CM Equity Partners (September 27, 2024) -- Progress Partners advisor
• XSB sold to Exiger (August 13, 2024) -- Progress Partners advisor
• Bibliotheca CloudLibrary sold to OCLC (April 2, 2024) -- Progress Partners advisor
• TrueData sold to ID5 -- Progress Partners exclusive (digital identity / data privacy)
• Agile Fleet sold to Banyan Software (June 2025) -- Progress Partners advisor

Distinguishing factor: Progress Partners is the deepest Boston-metro adtech, martech, and digital-media specialty boutique. MacShane's career deal list (AdsWizz / Pandora, Going.com / AOL) anchors a 20+ year buyer-relationship density across programmatic, ad-tech, and data-privacy strategics -- the firm's Wellesley headquarters anchors a steady pipeline of New England digital-media and martech founder-led sellers. The sister venture fund Progress Ventures gives the senior team continuous visibility into the early-stage adtech and martech ecosystem that feeds the M&A pipeline.

Best for: Founder-owned adtech, martech, digital-media, programmatic, or data-privacy companies with $5M-$15M EBITDA preparing for a strategic-acquirer exit. Best contact: Nick MacShane.

12. Shields & Company

HQ: Greater Boston (Wellesley / Needham metro) Founded: 1991 by Tom Shields Senior team: Tom Shields (Founder and Managing Director), Christopher Nicholas (Managing Partner; 15+ years M&A experience advising middle-market companies; previously an associate with Harris Williams & Co. in Richmond; based in Waltham, MA; ACG Boston board member; FINRA Series 7, 24, 63, 79). Deal size sweet spot: $20M-$200M generalist middle-market M&A Sectors: Generalist mid-market -- business services, consumer and retail, manufacturing and distribution, technology, life sciences, healthcare. The firm has completed approximately 200+ transactions over its 35-year history. Recent activity: Shields & Company's 2024-2026 specific deal disclosure is best verified directly via the firm's transactions page at shieldsco.com -- the firm's continuous middle-market practice over 35 years anchors sector depth in business services, consumer, and manufacturing rather than recent named transactions specifically.

Distinguishing factor: Shields & Company is one of the longest-operating Greater Boston generalist boutiques with 35 years of continuous practice and approximately 200+ closed transactions. The firm's sector breadth (services, consumer, manufacturing, tech, life sciences, healthcare) is the structural default for multi-sector founder-owned New England businesses where the asset profile spans more than one sub-vertical.

Best for: Multi-sector founder-owned businesses with $5M-$20M EBITDA in services, consumer, manufacturing, tech, or healthcare preparing for a senior-banker-led process. Best contact: Tom Shields (founder).

---

What Recent Boston-Area M&A Deals Show How These Advisors Actually Work?

Five recent verified Boston-tied closes that illustrate the deal-size band, the buyer-pool composition, and the structural advantage each advisor brings.

Acentus to Henry Schein (January 2025; Provident Healthcare Partners)

Provident Healthcare Partners served as exclusive financial advisor to Acentus on the January 2025 sale to Henry Schein. Acentus is a continuous-glucose-monitoring medical-supplier; Henry Schein is the publicly-traded medical and dental supplies distributor. Kevin Palamara (Provident Managing Director, with the firm since 2002) led the engagement. The deal demonstrates Provident's structural depth in the medical-supply distribution sub-sector and the firm's relationship density with publicly-traded healthcare strategics. Henry Schein's corp-dev team was the eventual buyer; the buyer-pool composition of CGM strategics, healthcare-distribution strategics, and PE platforms is exactly the buyer set Provident designs around in healthcare-services rollups.

Sassafras Software to TeamDynamix (April 23, 2025; Mirus Capital Advisors)

Mirus Capital Advisors served as exclusive financial advisor to Sassafras Software on the April 23, 2025 sale to TeamDynamix. Sassafras Software runs IT-asset-management and software-license-tracking products for higher education and government IT departments; TeamDynamix is an ITSM (IT Service Management) platform. Jason Arican (Mirus Director and software / SaaS lead) ran the engagement. The deal demonstrates Mirus's structural reach into the founder-owned-SaaS LMM band -- Sassafras was a founder-led New England software company at sub-$30M ARR, exactly the segment where Mirus's 38-year generalist depth and Arican's tech-specialty focus produce aligned senior-banker attention.

Vital Delivery Solutions to Copley Equity Partners (December 18, 2025; BellMark Partners)

BellMark Partners served as exclusive financial advisor to Vital Delivery Solutions on the December 18, 2025 sale to Copley Equity Partners. Vital Delivery Solutions is a New England business-services company; Copley Equity Partners is a Boston-area private-equity firm. The deal team included David Gesmondi (BellMark founder), Kellen Field, and Christopher Rea. The deal demonstrates BellMark's structural depth in the New England PE-platform buyer pool and the firm's senior-banker-only model -- Gesmondi personally ran the engagement, consistent with the firm's senior-MD-led process design.

Capstone Partners' Acquisition of TM Capital (December 2025; Capstone Partners)

The December 2025 Capstone Partners acquisition of TM Capital is the major Boston-bench consolidation event of 2025-2026. Capstone (Boston-headquartered; Huntington Bancshares subsidiary) added the legacy TM Capital roster to its 12 industry groups, including Brad Adams (Managing Director, Tech and Tech-Enabled Services; Boston) and Kevin Atchue (Managing Director). John Ferrara (Capstone founder, now CEO of the combined entity) leads the integration. Email migration from @tmcapital.com to @capstonepartners.com is in progress as of mid-2026; Boston founders contacting the firm should confirm the current address before sending engagement-letter discussions. The acquisition reshapes the Boston-area middle-market platform bench by removing TM Capital as a standalone option and consolidating its senior team under Capstone's bank-owned-platform tier.

Mobalytics to ESL FACEIT Group (March 2025; AGC Partners)

AGC Partners served as sole financial advisor to Mobalytics on the March 2025 sale to ESL FACEIT Group (owned by Saudi PIF / Savvy Games Group). Mobalytics is a video-game performance-analytics platform. Nate Hennings (AGC Partners) led the engagement. The deal demonstrates AGC's structural reach into the gaming-tech and consumer-software sub-sectors and the firm's relationship density with international strategic acquirers (ESL FACEIT is European; Saudi PIF is the underlying parent capital). For Boston-area tech founders evaluating AGC, the Mobalytics deal is a direct data point on how the firm's conference-circuit buyer-relationship density translates into actual cross-border close.

---

How Do I Pick the Right Boston M&A Advisor for My Situation?

The decision framework comes down to deal size + sub-vertical + ownership structure + buyer-pool geography.

For $20M-$300M EV healthcare-services rollups (physician, home health, specialty pharmacy, DME, behavioral health) → Provident Healthcare Partners is the Boston-default first-call with 28 years of continuous middle-market healthcare-services focus and a verified four-deal 2025 track record.

For $10M-$150M EV medical devices, diagnostics, life-science services, or biotech with strategy-consulting scope → Outcome Capital runs the strategy-led-execution model with senior-MD-tier engagement (Arnie Freedman, Oded Ben-Joseph, Peter Meyer).

For $10M-$500M EV biopharma, biotech, or medtech with integrated banking-and-strategy-consulting scope → Back Bay Life Science Advisors runs the integrated model with DNB Bank cross-border European acquirer reach.

For $50M-$500M EV biopharma, biotech, medtech, tools, or diagnostics → Aquilo Partners' Boston office brings the deepest cross-coast life-sciences-only specialty boutique with John Dyer leading the Boston bench.

For $50M-$1B+ EV healthcare services, HCIT, specialty pharmacy, behavioral health, payer tech (when balance-sheet financing matters) → Cain Brothers (KeyBanc Capital Markets healthcare division) is the largest dedicated healthcare M&A team with continuous Boston-area presence and KeyBanc balance-sheet capability.

For $10M-$100M EV generalist middle-market (consumer, industrial, services, healthcare, F&B, SaaS) at the smaller end → Mirus Capital Advisors is the deepest-rooted New England generalist boutique with 38 years and 300+ closed transactions.

For $20M-$200M EV generalist middle-market business services, healthcare, consumer, or industrial → BellMark Partners runs a senior-banker-only model with KeyBanc-pedigree founder Dave Gesmondi.

For $25M-$500M EV multi-sector deals where bank-owned-platform reach matters → Capstone Partners is the largest Boston-headquartered full-service middle-market platform with 12 industry groups, Huntington Bancshares parent, and December 2025 TM Capital integration.

For $50M-$1B+ EV pure tech, SaaS, AI, cybersecurity, defense tech, fintech, edtech → AGC Partners runs Boston's deepest pure-tech specialty boutique with six annual industry conferences worth of buyer-relationship density.

For $25M-$200M EV multi-sector deals across healthcare, business services, consumer, industrial, technology → Covington Associates runs Boston's longest-tenured multi-sector boutique with 35 years and approximately 252 lifetime deals.

For $15M-$150M EV adtech, martech, digital media, programmatic, or data privacy → Progress Partners is the deepest Boston-metro pure-adtech specialty boutique with 20+ years of continuous practice.

For $20M-$200M EV multi-sector generalist (services, consumer, manufacturing, tech, life sciences, healthcare) → Shields & Company is one of the longest-operating Greater Boston generalist boutiques with 35 years and 200+ closed transactions.

For framework comparisons with related frameworks, see our M&A data room guide, which covers what Boston advisors expect to see by week 1 of the engagement.

---

What Data Room Capabilities Do Boston Advisors Demand?

Boston-area biotech, healthcare-services, tech, and adtech sellers face a structurally harder confidentiality environment than most US metros, especially for Cambridge biotech where the Kendall Square ecosystem is under 2 square miles and the same handful of venture firms cover the majority of biotech investments. The Boston advisors who run consistently confidential processes all rely on specific data room capabilities. Five capabilities matter most:

1. Click-through NDA gates -- buyer-side users sign the NDA inside the data room before viewing any content, eliminating the email-attachment-NDA chain-of-custody problem that lets CIMs leak before signature; particularly critical for Cambridge biotech where leaked CIMs translate into competitor scientific-strategy reverse-engineering within 72 hours
2. Per-investor watermarks -- buyer email plus exact view timestamp embedded into every page so a leaked CIM has a forensic audit trail back to the specific buyer; the structural answer to Boston's overlapping-investor and overlapping-talent confidentiality risk
3. Page-level analytics -- senior banker can see at a glance which buyer is reading the financials versus which is reading the regulatory section once and skipping the rest, which informs the LOI follow-up sequence
4. Visitor groups for buyer tiering -- strategic acquirers, PE platform buyers, and competitor-adjacent buyers each see different document sets, with competitor-tier buyers blocked from clinical-data tables, customer-concentration tables, or unit-economics detail until LOI signed
5. Screenshot protection -- blocks and logs unauthorized capture attempts, deterring competitors from harvesting clinical-data tables and customer lists during data room visits

For Boston biotech specifically, the auto-indexing feature compresses Weeks 1-3 of the engagement timeline because buyers can search across the entire data room instead of chasing folder paths -- a meaningful benefit when the data room contains thousands of pre-clinical and clinical-trial-design pages. For solutions specifically targeted at M&A and private equity buyer-side workflows, Peony's M&A solution and PE solution pages cover the structural data room patterns most Boston advisors use. Custom domain means the data room URL reads as the seller's domain rather than a vendor URL -- a small detail that matters when strategic acquirers' corp-dev teams forward links internally. Smart Q&A centralizes buyer questions so the senior banker (or CFO) can answer once and surface the answer to every approved buyer rather than repeating the same answer across 15 separate email threads.

---

How Do Boston M&A Advisor Fees Work?

Boston-area specialty boutiques typically run a Lehman-style success fee scale plus retainer:

Sub-vertical-specialty firms (Provident on healthcare services, Aquilo on biotech, AGC on pure tech, Progress on adtech, Outcome Capital on medtech) sometimes charge at the higher end of the band given the buyer-relationship density they bring. Bank-owned-tier firms (Cain Brothers, Capstone Partners) typically run standard Lehman with a higher retainer floor ($75K-$150K) given the parent-bank cost structure. Pure generalist boutiques (Mirus, BellMark, Covington, Shields) typically run standard Lehman without the specialty premium. Bulge-bracket Boston offices (Goldman Sachs, Morgan Stanley) at $30M EV typically demand $250K+ retainer plus a $750K+ minimum success fee floor regardless of deal value -- structurally inefficient at the LMM band.

For full pricing detail on data room costs, Peony Business at $40 per admin per month replaces the $15K-$50K per-deal data room cost most Boston boutiques used to bill as expense reimbursement -- the platform fee shows up in the seller's expense column rather than the advisor's pass-through column.

---

Boston M&A Advisor FAQs

What's the difference between a Boston M&A boutique and a bulge-bracket bank like Goldman or Morgan Stanley for a $50M deal?

For Boston-area sellers between $5M and $200M EV, the difference is structural: bulge-bracket banks are built around $200M+ engagements where senior MD time is allocated to the largest fee-payers, while specialty boutiques are built around the lower-middle-market band where senior bankers run buyer calls personally. A $50M EV Boston biotech sell-side at Goldman or Morgan Stanley is staffed by a VP-and-analyst team, with the sector MD showing up for the pitch and the management presentation, then disappearing -- everything else routes through staff. Most Boston boutiques compete for the $25M-$200M EV band by structural design with senior-banker-led models, sub-vertical specialty depth, and minimum-fee floors aligned to the LMM band. Two firms operate as bank-owned platforms (Cain Brothers as a KeyBanc Capital Markets division for healthcare deals; Capstone Partners as a Huntington Bancshares subsidiary for full-service middle-market reach). The structural test: ask any bulge-bracket pitcher to commit in writing to which senior banker (MD or above) will be on every buyer call. Most won't.

Should I hire a boutique M&A advisor or Cain Brothers / KeyBanc for a $50M Boston biotech sale?

For a $50M Boston biotech sale, the choice between a true independent boutique (Aquilo Partners' Boston office, Outcome Capital, Back Bay Life Science Advisors) and Cain Brothers as a KeyBanc Capital Markets division breaks on three factors: balance-sheet need, comms protocol, and senior-banker autonomy. Cain Brothers' Boston-area healthcare practice anchors the bank-owned-boutique tier in New England M&A -- it gives sellers access to KeyBanc's debt capital markets and equity capital markets capability, which matters if the buyer set includes PE platforms requiring staple financing. The cost is comms protocol: KeyBanc-mandated review chains and Fortune-500 compliance overhead can slow the senior banker's response cycle. By contrast, Aquilo Partners' Boston office, Outcome Capital, and Back Bay LSA all run pure independent boutiques with no parent-bank approval layer. For a $50M biotech with no balance-sheet financing dependency and a strategic-acquirer-only buyer pool, the independent boutique is structurally better.

How does Capstone Partners' Huntington Bancshares ownership affect Boston founders' deal-team experience?

Capstone is Boston-headquartered (176 Federal Street) but is a Huntington Bancshares subsidiary (acquired June 16, 2022). The ownership structure creates three deal-team experience differences: buyer-pool reach extends through Huntington's middle-market commercial banking footprint, the December 2025 TM Capital acquisition folded the legacy TM Boston team into Capstone (Brad Adams in tech, Kevin Atchue), and the special situations practice (Geoffrey Frankel) brings restructuring capability that pure-LMM boutiques rarely offer in-house. The trade-off is parent-bank compliance overhead on engagement-letter terms and obvious cross-sell incentives. Crista Gilmore (promoted to MD March 21, 2025) and John Ferrara (founder, now CEO of the combined entity) anchor the senior bench.

Should I sell my Boston biotech now or wait for the IPO market to reopen?

For a Boston-area biotech founder with a clinical-stage asset, the M&A-now-versus-IPO-later decision is the Boston-distinguishing exit question of 2025-2026 because the Massachusetts IPO market is essentially closed: 1 MA-based biotech IPO in all of 2025 (Sionna Therapeutics) versus 6 MA biotech IPOs in 2024 per MassBio. Five structural inputs decide: cash runway, strategic-buyer pipeline interest level, clinical-data inflection point timing, Cambridge lab real-estate cost pressure (28% vacancy at Q4 2025 per CBRE), and large-cap pharma corp-dev pipeline-gap activity (Pfizer's $10B Metsera deal, Sanofi-Blueprint $9-9.5B June 2025, Eli Lilly-Verve June 2025, Eli Lilly-Adverum October 2025). The structural recommendation: hire the same advisor for both options and ask them to model the M&A outcome at three valuation breakpoints alongside the IPO scenario at two pricing breakpoints. Boston advisors who run this decision most often are Aquilo Partners (John Dyer), Outcome Capital, Back Bay Life Science Advisors, and Cain Brothers' Boston-area healthcare team.

What's a reasonable success fee for a $50M Boston biotech sell-side mandate?

Boston M&A advisors at the $50M EV biotech band typically charge 1.5-2.5% blended success fee plus a $50K-$150K retainer credited against the success fee at close, with tail period of 12-24 months standard. The standard Lehman scale (5/4/3/2/1) on $50M produces approximately $700K of success fees -- about 1.4% blended. Specialty firms with deeper buyer relationships sometimes charge at the higher end. Bank-owned-tier firms (Cain Brothers, Capstone) typically run standard Lehman with a higher retainer floor. Bulge-bracket Boston offices at this deal size typically demand a $250K+ retainer plus a $750K minimum success fee floor regardless of deal value -- structurally inefficient at the $50M EV band.

How do I evaluate a Boston boutique M&A advisor's biotech track record?

Verify the track record through three independent sources: the firm's transaction wall cross-checked against PR Newswire, BusinessWire, BioPharma Dive, STAT News, FierceBiotech, Endpoints News, and the buyer's own SEC 8-K filings; MassBio's Year-End Funding Report, Foley Hoag Healthcare and Life Sciences Deal Trends review, and Axial league tables; and direct seller references for two CEOs from biotech closes in the last 12 months. The single highest-signal question: ask for the engagement letter date and close date on the last three closed biotech deals -- 6-9 months is typical, 12+ months a warning sign. Boston biotech advisors with verified 2025 closes include Provident Healthcare (4 deals: Acentus / Henry Schein, Elder Care / Rallyday, CPS Infusion / Seven Hills, Meperia / Diversis), Aquilo Partners (Durect ALZET / Lafayette $17.5M; Adverum / Eli Lilly closed December 9, 2025), Outcome Capital (RealizedCare / XRHealth February 2025), and Mirus Capital (Sassafras / TeamDynamix April 2025).

Are biotech VC's M&A advisor referrals actually objective or pre-arranged?

The objectivity of biotech-VC M&A advisor referrals is a structural concern in Boston specifically because the Cambridge biotech-VC ecosystem (Polaris Partners, Atlas Venture, Third Rock Ventures, Flagship Pioneering, Bain Capital Life Sciences, MPM Capital, F-Prime Capital, Mass General Brigham Ventures) is small enough that the same M&A boutiques recur across portfolios. Three patterns to watch: the repeat-referral pattern (institutional vs case-by-case), the buy-side-hat conflict (advisors with historical buy-side mandates from named acquirers), and the LP-overlap pattern. The mechanical fix: run the pitch process with three boutiques where at least one is selected without VC referral. Boston independents earning their position without VC pre-arrangement include Outcome Capital, Provident Healthcare, Aquilo Partners' Boston office, Back Bay LSA, and Mirus Capital.

How do I structure an M&A engagement letter for a sub-IND biotech without paying for nothing?

For a sub-IND or pre-clinical Boston biotech, six engagement-letter clauses earn their drafting time: 100% retainer credit against the success fee at close; minimum success fee floor in the $300K-$500K range; tail period excluded-acquirer list dated at signing; competitor-exclusion clause barring the advisor from competing biotechs in the same therapeutic area; termination-for-cause clause with 30-day cure period; and expense pass-through cap (typical $25K-$50K). Boston boutiques most willing to negotiate sub-IND-friendly terms include Back Bay Life Science Advisors (integrated banking-and-consulting model), Outcome Capital (strategy-led-execution model), and Aquilo Partners' Boston office.

How do I run a confidential biotech sell-side process in Cambridge without leaking to the local VC community?

The Cambridge biotech-confidentiality problem is structurally harder than any other US M&A confidentiality challenge because the Kendall Square ecosystem is under 2 square miles, the same 8-12 venture firms cover the majority of Series-A-through-Series-C biotech investments, the same handful of CROs and clinical sites serve overlapping customer bases, and senior scientific talent moves between portfolio companies on 18-30 month cycles. The five mechanical fixes: teaser-first NDA process, deal-team restricted to founder-CEO + CFO + one VP Clinical Development until LOI signed, board-resolution carve-out for conflicted directors, KOL/CRO reference checks only after exclusivity, and competitor-exclusion clauses with tiered data room access. Boston firms running confidential biotech processes by structural design include Aquilo Partners, Outcome Capital, Back Bay Life Science Advisors, and Provident Healthcare. Peony per-investor watermarks embed buyer email plus exact view timestamp into every page; Peony screenshot protection blocks and logs unauthorized capture attempts.

Provident vs Outcome Capital vs Aquilo Partners for life sciences M&A in Boston -- how do I choose?

The Provident vs Outcome Capital vs Aquilo choice for a Boston life-sciences seller breaks on sub-vertical and asset stage. Provident (260 Franklin Street; founded 1998) is the structural default for healthcare-services M&A: physician practices, home health, specialty pharmacy, infusion, DME, behavioral health, dental. Best contact: Kevin Palamara. Outcome Capital (Boston; Arnie Freedman, Oded Ben-Joseph) is the structural default for medical devices, diagnostics, life-sciences services, and biotech where strategy-led execution matters. Aquilo Partners' Boston office (John Dyer) is the structural default for biopharma, biotech, medtech, tools, and diagnostics M&A and licensing at $50M-$500M EV. The decision tree: healthcare-services sell-side at $20-300M EV goes to Provident; medical-device or diagnostics with strategy-consulting scope goes to Outcome Capital; biopharma at $50M+ EV goes to Aquilo.

---

Bottom Line

For Boston-area founders selling between $5M and $200M EV, the structural answer is almost always a sub-vertical specialty boutique built around the LMM band, not a bulge-bracket bank built around $200M+ engagements. The 12 firms covered here are the verified active 2025-2026 Boston-area bench: Cain Brothers (KeyBanc Capital Markets healthcare division) for the bank-owned-boutique-tier healthcare anchor; Provident Healthcare Partners, Outcome Capital, Back Bay Life Science Advisors, and Aquilo Partners' Boston office for the Healthcare and Life-Sciences band; Mirus Capital Advisors, BellMark Partners, and Capstone Partners for the Generalist Middle-Market band; and AGC Partners, Covington Associates, Progress Partners, and Shields & Company for the Tech / Adtech / Multi-Sector Specialty band.

The structural decision tree: pick the firm whose sub-vertical specialty matches your sub-sector, whose deal-size sweet spot matches your EV band, and whose ownership structure (true-independent vs bank-owned-tier) aligns with your balance-sheet-financing needs and engagement-letter-term flexibility preferences. Then ask the firm to name the specific senior banker who will personally run your process from CIM to close, and require it in writing in the engagement letter. Boston's structural confidentiality environment -- Cambridge biotech ecosystem under 2 square miles, overlapping VC portfolio buyer set, scientific talent moving on 18-30 month cycles, lab vacancy at 28% record high -- means the right advisor pick at the right deal size band is as load-bearing as any decision in the founder's exit. And the IPO-vs-M&A pivot for biotech specifically (1 MA-based biotech IPO in all of 2025 versus 6 in 2024) means the M&A path is the structural default for clinical-stage Boston founders in 2026, not the alternative.

For the M&A data room checklist covering what Boston advisors expect to see by Week 1 of the engagement, our companion guide walks through the full folder-and-file structure. For the M&A due diligence process guide covering what diligence cycles look like at each stage of the Boston M&A process, our process companion covers the full Week 1 to close timeline. For the M&A click-through NDA mechanics covering how NDA gating works inside the data room before any CIM circulation, our NDA companion walks through the buyer-side experience.

If your situation is closer to an IPO than a sale, our IPO readiness checklist 2026 covers the dual-track and IPO-prep alternative path -- particularly relevant for Boston biotech founders evaluating whether to wait for the IPO window to reopen or move to a strategic-acquirer process now. For other US metros, see our SF/Bay M&A advisor guide, NYC M&A advisor guide, LA M&A advisor guide, Dallas guide, Chicago guide, Atlanta guide, and Houston guide.

---

Related Resources

• M&A Data Room Checklist 2026 -- what Boston advisors expect to see ready by Week 1
• M&A Due Diligence Process Guide -- the Week-1-to-close process companion
• M&A Click-Through NDA Mechanics -- buyer-side NDA experience inside the data room
• IPO Readiness Checklist 2026 -- dual-track and IPO-prep alternative path (Boston biotech-relevant)
• SF/Bay M&A Advisor Guide -- West Coast biotech and tech equivalent metro
• NYC M&A Advisor Guide -- East Coast financial-services equivalent metro
• LA M&A Advisor Guide -- West Coast media and consumer metro
• Dallas M&A Advisor Guide -- Texas / Southwest metro
• Chicago M&A Advisor Guide -- Midwest metro
• Atlanta M&A Advisor Guide -- Southeast metro
• Houston M&A Advisor Guide -- Texas energy metro
• Peony M&A Solution -- data room workflows for M&A advisors
• Peony Private Equity Solution -- buyer-side PE workflows
• Peony Pricing -- replaces $15K-$50K per-deal data room expense